Deutsche Bank set a €25.00 ($29.07) price objective on Evotec (ETR:EVT) in a research report released on Thursday morning, Borsen Zeitung reports. The brokerage currently has a buy rating on the stock.
Separately, Berenberg Bank set a €28.00 ($32.56) price objective on Evotec and gave the stock a neutral rating in a research note on Thursday, August 1st.
EVT opened at €19.75 ($22.97) on Thursday. The firm has a market cap of $2.94 billion and a PE ratio of 38.88. The company has a quick ratio of 3.01, a current ratio of 3.24 and a debt-to-equity ratio of 99.79. The business has a fifty day simple moving average of €24.26 and a 200-day simple moving average of €22.85. Evotec has a fifty-two week low of €15.00 ($17.44) and a fifty-two week high of €27.29 ($31.73).
Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company operates in two segments, EVT Execute and EVT Innovate. The EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody platform; INDiGO, a program for accelerating the early drug candidates into the clinic stage; integrated chemistry, manufacturing, and control services; and integrated drug discovery services.
Featured Story: How Do Tariffs Affect Trade Balances?
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.